Menu Search
Equities

Insmed Inc

0JAV:LSE

Insmed Inc

Actions
  • Price (USD)24.61
  • Today's Change0.00 / 0.00%
  • Shares traded117.00
  • 1 Year change+32.60%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 17:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

  • Revenue in USD (TTM)315.49m
  • Net income in USD-746.89m
  • Incorporated1999
  • Employees912.00
  • Location
    Insmed Inc700 Us Highway 202/206BRIDGEWATER 08807United StatesUSA
  • Phone+1 (908) 977-9900
  • Websitehttps://insmed.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		INSM:NSQ since
announced		Transaction
value
Adrestia Therapeutics LtdDeal completed17 Jul 202317 Jul 2023Deal completed20.24%--
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.